| 摘要 |
The invention relates to a method for identifying compounds that act as enhancers or inhibitors of matrix metalloproteinase (MMP) activity. The invention also relates to a method for diagnosing whether or not a subject is at risk of developing, or has, a disease associated with pathogenic APP processing. The invention further relates to the use of type I transmembrane protease inhibitors, in particular inhibitors of MMP 16, MMP 14 or MMP 15 activity, for preventing or treating diseases associated with pathogenic APP processing, such as Alzheimer's disease. |
